What it is
FOXO4-DRI is a synthetic peptide of 46 amino acids, every one of them a D-amino acid — the mirror-image form of the amino acids the body uses. It was designed to make senescent cells die. Senescent cells are cells that have stopped dividing after damage or with age but resist dying; they release inflammatory signals, and their build-up is linked to features of ageing in animals.
It was first described in Cell on 23 March 2017 by Baar and colleagues in the de Keizer laboratory at Erasmus University Medical Center in Rotterdam (PMID 28340339). The paper's methods section gives the full sequence, written in lower case to mark the D-form:
| Property | Value | Source |
|---|---|---|
| Length | 46 amino acids, all D-form | Baar et al. 2017, methods |
| Sequence | ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg | Baar et al. 2017, methods |
| Molecular weight | 5,358.2 | Baar et al. 2017, methods |
| Manufacturer in the study | Pepscan, Lelystad, >95% purity | Baar et al. 2017, methods |
| Human trials registered | 0 | ClinicalTrials.gov API, 2026-11-16 |
Two parts in one chain. The paper says the peptide was "designed as a fusion with HIV-TAT", a short sequence that lets cargo cross cell membranes. Reading the sequence, the last 13 residues — qpprrrqrrkkrg backwards — are that TAT segment in reversed order; the rest copies a region of FOXO4 the authors chose because it is conserved between humans and mice but differs from the related FOXO1 and FOXO3 (our reading of the sequence against the paper's description).
How it is meant to work
Inside a senescent cell, the protein FOXO4 holds the tumour-suppressor protein p53 in the nucleus, in a way that keeps the cell alive. FOXO4-DRI competes with FOXO4 for p53. In the 2017 experiments, the peptide bound p53 more strongly than FOXO4 did, p53 left the nucleus, and the senescent cells died by apoptosis, the cell's own shutdown programme. The paper also reports lower levels of p21Cip1, the cell-cycle brake that p53 controls — the protein whose name the nootropic research peptide p21 shares, though the two are unrelated. Treating senescent human fibroblasts with it reduced their numbers while normal cells were largely spared (Baar et al. 2017).
"Retro-inverso" is the design trick: using D-amino acids in reversed order can produce a peptide that presents its side chains much like the original but is not broken down by the body's enzymes. The paper cites this as the reason for the choice; it did not measure how long the peptide lasts in a person, because no person received it.
What the evidence shows
| Evidence | Who or what | Finding | Source |
|---|---|---|---|
| Cell studies | Senescent human fibroblasts | p53 left the nucleus; senescent cells died | Baar 2017 |
| Chemotherapy damage | Mice given doxorubicin | Peptide neutralised the drug's toxicity (body-weight and liver measures) | Baar 2017 |
| Fast-ageing mice | XpdTTD/TTD mice | Fitness, fur density and kidney function restored | Baar 2017 |
| Naturally aged mice | 110+ weeks old | Plasma urea and creatinine improved at 30 days | Baar 2017 |
| People | — | No registered trial, no published result | ClinicalTrials.gov; PubMed |
The mice received 5 mg per kg of body weight three times, every other day, by injection (Baar et al. 2017, figure legends). That figure is reported because it is the published animal protocol; there is no human dose on any record, because there is no human study.
Since 2017, the work that names FOXO4-DRI is mostly cell and animal research in other settings — for example a 2021 study using it on senescence-like fibroblasts after radiotherapy in lung-cancer models (JCI Insight, PMID 34877934). PubMed holds 19 records naming it, five of them reviews, and none tagged as a clinical or randomised trial (searched 2026-11-16).
What is not established: whether FOXO4-DRI is safe in people, whether it reaches human tissues, what it does to healthy cells over months, and whether any of the mouse effects occur in humans. An animal result is not a human result, and here there is no human result at all.
Where it stands
FOXO4-DRI is not approved by any regulator and has no registered human trial. It circulates as a research chemical on vendor sites that describe it as an anti-ageing peptide; those descriptions rest on the 2017 mouse study. Peptifact's FOXO4-DRI dosage page reports what vendors and forums cite. The library's overview of peptides sold for longevity sets it beside epitalon and the other compounds marketed on ageing. Anyone considering it is weighing a substance with no human safety record, a decision for a doctor.
A second research peptide organised around p53 is the p53-fragment peptide PNC-27, aimed at cancer cells rather than senescent ones, with a record that is equally pre-clinical.
Sources opened 2026-11-16: Baar et al., Cell 2017 (PMID 28340339, full text via PubMed Central PMC5556182); Krimpenfort and Berns, Cell 2017 commentary (PMID 28340347); Meng et al., JCI Insight 2021 (PMID 34877934); PubMed E-utilities and ClinicalTrials.gov API v2 searches.
